Abnormal Glycosphingolipid Metabolism C4025350
A disorder affecting how the body processes glycosphingolipids, which are important for cell function. This includes conditions like Fabry disease. Treatment may involve enzyme replacement or other therapies.
Key facts at a glance
- ICD-10
- E88.9
- ICD-11
- 5A00.0
- Body system
- metabolic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Cardiac abnormalities
Heart valve disease, cardiomyopathy, or conduction abnormalities affecting heart function.
Seek immediate care for chest pain, shortness of breath, palpitations, or fainting episodes.
Stroke or TIA
Ischemic stroke or transient ischemic attack due to vascular involvement.
Seek emergency care immediately for sudden weakness, speech difficulty, vision changes, or severe headache.
Fatigue and weakness
(constitutional)Persistent tiredness and lack of energy due to anemia and metabolic abnormalities.
Frequency: 70-80% of patients
Hepatosplenomegaly
(constitutional)Enlargement of the liver and spleen due to accumulation of glycosphingolipids.
Frequency: 80-90% of patients
Bone pain and fractures
(musculoskeletal)Bone pain, osteopenia, and increased risk of fractures due to lipid accumulation in bone marrow.
Frequency: 50-60% of patients
Easy bruising and bleeding
(hematologic)Bruising and bleeding tendencies due to low platelet count and abnormal platelet function.
Frequency: 40-50% of patients
Angiokeratomas
(dermatologic)Dark red to purple raised skin lesions, typically appearing in a bathing suit distribution.
Frequency: 30-40% of patients
Peripheral neuropathy
(neurologic)Burning pain, tingling, or numbness in hands and feet due to nerve involvement.
Frequency: 40-50% of patients
Abdominal pain and fullness
(gastrointestinal)Recurrent abdominal discomfort due to organ enlargement and gastrointestinal involvement.
Frequency: 30-40% of patients
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Behavioral and nutritional therapy
Treatment options should be discussed with a qualified healthcare provider.
Enzyme replacement therapy
Intravenous infusion of recombinant enzyme to replace deficient activity in glycosphingolipid metabolism disorders such as Fabry disease, reducing substrate accumulation.
Substrate reduction therapy
Oral medications that reduce production of accumulated glycosphingolipids by inhibiting key enzymes in the synthesis pathway.
Additional treatment options
Organ damage surveillance
Regular imaging and laboratory monitoring for cardiac, renal, and neurological complications from glycosphingolipid accumulation.
monitoringLow glycolipid dietary modifications
Dietary adjustments to limit intake of foods high in glycosphingolipids, potentially reducing substrate burden and supporting metabolic management.
dietaryDialysis or kidney transplant support
Renal replacement therapy coordination for patients with Fabry nephropathy who develop kidney failure secondary to glycosphingolipid accumulation.
procedureWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Abnormal Glycosphingolipid Metabolism C4025350?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Ter Heine R, et al. Management of Gaucher disease: ICGG 2022 guidelines. Blood Adv. 2022;6(8):2558-2571.
European Study Group on Fabry Disease. Consensus recommendations for Fabry disease management. Kidney Int Suppl. 2020;10(1):e1-e30.
Platt FM, et al. Lysosomal storage disorders. Nat Rev Dis Primers. 2017;3:17065.
American College of Medical Genetics and Genomics. Clinical practice recommendations for Fabry disease. Genet Med. 2020;22(10):1675-1687.
Schiffmann R, et al. Glycosphingolipid disorders and their treatment. Ann Neurol. 2019;85(6):848-858.
Biegstraaten M, et al. European recommendations for initial management of Gaucher disease. Orphanet J Rare Dis. 2018;13(1):117.
Hughes DA, et al. Long-term miglustat therapy in type 1 Gaucher disease. Mol Genet Metab. 2019;126(2):S50.
Scriver CR, et al., eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. McGraw-Hill; 2021. Chapter 150: Glycosphingolipid storage disorders.
Weinstein M, et al. Enzyme replacement therapy outcomes in Gaucher disease: meta-analysis. J Inherit Metab Dis. 2021;44(5):1189-1202.
International Collaborative Gaucher Group. Consensus statements on the management of Gaucher disease. Clin Ther. 2020;42(12):2245-2257.
Medication Comparisons
Compare medications used to treat Abnormal Glycosphingolipid Metabolism C4025350. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy